Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus nephritis
Biotech
GSK aims to extend lupus dominance via $300M T-cell engager deal
Not content with getting the first lupus drug to market, GSK is paying $300 million upfront for an asset it believes could benefit further patients.
James Waldron
Oct 29, 2024 8:00am
FDA places Kezar lupus trial in hold following 4 patient deaths
Oct 7, 2024 5:50am
Kezar suspends key lupus study after 4 deaths
Sep 30, 2024 11:23am
Kezar drops solid tumor yet to prove its worth in phase 1 trial
Aug 14, 2024 5:09am
Kyverna's CAR-T relapse in lupus dents autoimmune hopes
Jun 17, 2024 8:51am
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Apr 16, 2024 10:05am
